CN106794178A - 去势治疗相关症状的治疗 - Google Patents

去势治疗相关症状的治疗 Download PDF

Info

Publication number
CN106794178A
CN106794178A CN201580048887.4A CN201580048887A CN106794178A CN 106794178 A CN106794178 A CN 106794178A CN 201580048887 A CN201580048887 A CN 201580048887A CN 106794178 A CN106794178 A CN 106794178A
Authority
CN
China
Prior art keywords
compound
day
dose
treatment
males
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580048887.4A
Other languages
English (en)
Chinese (zh)
Inventor
C.T.本森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202110830219.4A priority Critical patent/CN113521068A/zh
Priority to CN201810348598.1A priority patent/CN108440497A/zh
Priority to CN202110871107.3A priority patent/CN113651797A/zh
Publication of CN106794178A publication Critical patent/CN106794178A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
CN201580048887.4A 2014-09-11 2015-09-08 去势治疗相关症状的治疗 Pending CN106794178A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202110830219.4A CN113521068A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN201810348598.1A CN108440497A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN202110871107.3A CN113651797A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049192P 2014-09-11 2014-09-11
US62/049192 2014-09-11
PCT/US2015/048801 WO2016040234A1 (en) 2014-09-11 2015-09-08 Treatment of androgen deprivation therapy associated symptoms

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202110830219.4A Division CN113521068A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN201810348598.1A Division CN108440497A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN202110871107.3A Division CN113651797A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗

Publications (1)

Publication Number Publication Date
CN106794178A true CN106794178A (zh) 2017-05-31

Family

ID=54151401

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202110830219.4A Pending CN113521068A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN201580048887.4A Pending CN106794178A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN201810348598.1A Pending CN108440497A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN202110871107.3A Pending CN113651797A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110830219.4A Pending CN113521068A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810348598.1A Pending CN108440497A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗
CN202110871107.3A Pending CN113651797A (zh) 2014-09-11 2015-09-08 去势治疗相关症状的治疗

Country Status (23)

Country Link
US (4) US10758515B2 (enExample)
EP (2) EP3191094B1 (enExample)
JP (4) JP6893171B2 (enExample)
KR (5) KR20210083370A (enExample)
CN (4) CN113521068A (enExample)
AP (1) AP2017009795A0 (enExample)
AU (2) AU2015315431C1 (enExample)
BR (2) BR112017002449B1 (enExample)
CA (2) CA2956514C (enExample)
EA (2) EA034553B1 (enExample)
ES (1) ES2779978T3 (enExample)
HK (1) HK1252811A1 (enExample)
IL (3) IL279209B2 (enExample)
JO (2) JOP20180072A1 (enExample)
MA (1) MA45416A (enExample)
MX (3) MX373322B (enExample)
MY (2) MY195767A (enExample)
NZ (1) NZ728612A (enExample)
SG (2) SG11201701630VA (enExample)
TW (1) TWI616201B (enExample)
UA (1) UA120099C2 (enExample)
WO (1) WO2016040234A1 (enExample)
ZA (1) ZA201802680B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
US20180185347A1 (en) * 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541749A (zh) * 2006-11-20 2009-09-23 伊莱利利公司 作为雄激素受体调节剂的四氢环戊二烯并[b]吲哚化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007536A (es) * 2003-01-13 2005-10-20 Gtx Inc Sintesis a gran escala de moduladores de receptor de androgeno selectivos.
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) * 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
JP2009538873A (ja) 2006-05-31 2009-11-12 グラクソ グループ リミテッド 新規複素環化合物
MX2009000714A (es) * 2006-07-19 2009-07-27 Osurf Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.
US7443672B2 (en) 2006-10-03 2008-10-28 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Video graphics array (VGA) card assembly
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
MX2010006972A (es) * 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
US8003689B2 (en) * 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR078862A1 (es) * 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CN102234287B (zh) * 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
JP2012149054A (ja) * 2010-12-27 2012-08-09 Dainippon Sumitomo Pharma Co Ltd Ｎ−置換−環状アミノ誘導体からなる医薬
LT2915804T (lt) * 2012-10-31 2019-06-10 Fujifilm Toyama Chemical Co., Ltd. Nauji amino dariniai arba jo druskos kaip tnf alfa inhibitoriai
JP6469692B2 (ja) * 2013-12-09 2019-02-13 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541749A (zh) * 2006-11-20 2009-09-23 伊莱利利公司 作为雄激素受体调节剂的四氢环戊二烯并[b]吲哚化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. ROHAYEM等: "Antiandrogene Therapie des Prostatakarzinoms，Indikation und systemische Folgen", 《DER UROLOGE》 *
PING YI等: "Disposition and Metabolism of LY2452473, a Selective Androgen Receptor Modulator (SARM), in Humans", 《DRUG METABOLISM AND DISPOSITION》 *
WENQING GAO等: "Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats", 《ENDOCRINOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物

Also Published As

Publication number Publication date
AP2017009795A0 (en) 2017-03-31
AU2015315431A1 (en) 2017-03-09
KR102024493B1 (ko) 2019-09-23
US10799478B2 (en) 2020-10-13
KR20220132669A (ko) 2022-09-30
KR102619415B1 (ko) 2024-01-02
IL258651A (en) 2018-06-28
US10758515B2 (en) 2020-09-01
JP2019089795A (ja) 2019-06-13
IL250291B (en) 2020-09-30
US20200390744A1 (en) 2020-12-17
US20240148694A1 (en) 2024-05-09
KR20210083370A (ko) 2021-07-06
WO2016040234A1 (en) 2016-03-17
BR112017002449A2 (pt) 2017-12-05
US20170172992A1 (en) 2017-06-22
EP3191094B1 (en) 2020-02-19
JP6893171B2 (ja) 2021-06-23
HK1252811A1 (en) 2019-06-06
JOP20180072A1 (ar) 2019-01-30
AU2015315431B2 (en) 2018-03-08
CN113651797A (zh) 2021-11-16
EA201891008A2 (ru) 2018-09-28
AU2015315431C1 (en) 2018-08-02
EP3191094A1 (en) 2017-07-19
JP2017527584A (ja) 2017-09-21
KR20190015628A (ko) 2019-02-13
CA3067289A1 (en) 2016-03-17
JP7349480B2 (ja) 2023-09-22
EA034553B1 (ru) 2020-02-19
MA45416A (fr) 2019-04-24
IL279209B2 (en) 2023-02-01
EA201790220A1 (ru) 2017-07-31
AU2018202714B2 (en) 2019-06-20
BR122018007412B1 (pt) 2022-08-23
BR112017002449B1 (pt) 2022-08-09
IL279209A (en) 2021-01-31
EA201891008A3 (ru) 2019-03-29
IL258651B (en) 2021-02-28
CA3067289C (en) 2023-04-04
CN108440497A (zh) 2018-08-24
MY195767A (en) 2023-02-10
MX2017003140A (es) 2017-05-23
ES2779978T3 (es) 2020-08-21
MX391447B (es) 2025-03-21
MX2021014120A (es) 2022-01-04
JP6938550B2 (ja) 2021-09-22
SG10201809673RA (en) 2018-12-28
IL250291A0 (en) 2017-03-30
TW201618782A (zh) 2016-06-01
JO3609B1 (ar) 2020-08-27
JP2023145479A (ja) 2023-10-11
JP2022000432A (ja) 2022-01-04
US20190111039A1 (en) 2019-04-18
TWI616201B (zh) 2018-03-01
CA2956514C (en) 2023-04-18
AU2018202714A1 (en) 2018-05-17
MX373322B (es) 2020-05-21
MY198753A (en) 2023-09-23
ZA201802680B (en) 2020-08-26
SG11201701630VA (en) 2017-03-30
KR20170040338A (ko) 2017-04-12
IL279209B (en) 2022-10-01
CN113521068A (zh) 2021-10-22
EA033606B1 (ru) 2019-11-08
UA120099C2 (uk) 2019-10-10
CA2956514A1 (en) 2016-03-17
NZ728612A (en) 2018-03-23
EP3375444A1 (en) 2018-09-19
KR20180041268A (ko) 2018-04-23

Similar Documents

Publication Publication Date Title
US20240148694A1 (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508A1 (en) Treatment of androgen deprivation therapy associated symptoms
HK1233508B (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170531

RJ01 Rejection of invention patent application after publication